Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hyloris Pharmaceuticals SA ( (DE:52U) ) just unveiled an update.
Hyloris Pharmaceuticals has signed an exclusive license and supply agreement granting Finland’s Orion Corporation rights to register, market and commercialize Hyloris’ ready-to-use intravenous pantoprazole in the EU, UK, Switzerland and Norway. The RTU IV formulation, which eliminates the need for reconstitution required by current lyophilized products, is aimed at simplifying hospital workflows, cutting preparation time and labour costs, and maintaining equivalent efficacy for high-volume gastric-acid indications, in a territory where more than 50 million vials of pantoprazole IV are used annually. Under the deal, Orion will handle regulatory and commercial activities using its strong hospital footprint, while Hyloris will supply product via its manufacturing network and receive upfront and milestone payments plus a substantial minority share of in-market sales, reinforcing its strategy of building a portfolio of differentiated, practical hospital medicines and deepening its commercial relationship with Orion.
The most recent analyst rating on (DE:52U) stock is a Buy with a EUR14.30 price target. To see the full list of analyst forecasts on Hyloris Pharmaceuticals SA stock, see the DE:52U Stock Forecast page.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a Belgium-based specialty biopharmaceutical company that focuses on reinventing and optimizing existing medications through reformulation and repurposing to address unmet medical needs. Leveraging streamlined regulatory pathways to shorten development timelines and reduce risk, Hyloris has a portfolio of more than 30 products and candidates, including 25 value-added medicines and several high-barrier generics, with early commercial products such as Sotalol IV for atrial fibrillation and Maxigesic IV for non-opioid post-operative pain, targeting hospital and specialty care markets worldwide.
Average Trading Volume: 9,767
Current Market Cap: €221.2M
For an in-depth examination of 52U stock, go to TipRanks’ Overview page.